- Home
- RYN vs LGND Comparison
RYN vs LGND Comparison
Compare RYN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- LGND
- Stock Information
- Founded
- RYN 1926
- LGND 1987
- Country
- RYN United States
- LGND United States
- Employees
- RYN N/A
- LGND 68
- Industry
- RYN Real Estate Investment Trusts
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- RYN Real Estate
- LGND Health Care
- Exchange
- RYN Nasdaq
- LGND Nasdaq
- Market Cap
- RYN 4.0B
- LGND 3.2B
- IPO Year
- RYN N/A
- LGND 1992
- Fundamental
- Price
- RYN $26.25
- LGND $182.63
- Analyst Decision
- RYN Hold
- LGND Strong Buy
- Analyst Count
- RYN 4
- LGND 8
- Target Price
- RYN $28.00
- LGND $144.71
- AVG Volume (30 Days)
- RYN 1.1M
- LGND 139.7K
- Earning Date
- RYN 11-05-2025
- LGND 08-05-2025
- Dividend Yield
- RYN 10.98%
- LGND N/A
- EPS Growth
- RYN 389.17
- LGND N/A
- EPS
- RYN 4.92
- LGND N/A
- Revenue
- RYN $1,239,943,000.00
- LGND $181,488,000.00
- Revenue This Year
- RYN N/A
- LGND $18.41
- Revenue Next Year
- RYN $4.07
- LGND $18.87
- P/E Ratio
- RYN $5.35
- LGND N/A
- Revenue Growth
- RYN 40.53
- LGND 53.40
- 52 Week Low
- RYN $21.84
- LGND $81.74
- 52 Week High
- RYN $32.88
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- RYN 51.55
- LGND 78.10
- Support Level
- RYN $25.76
- LGND $176.33
- Resistance Level
- RYN $27.06
- LGND $184.26
- Average True Range (ATR)
- RYN 0.45
- LGND 5.00
- MACD
- RYN 0.01
- LGND 0.41
- Stochastic Oscillator
- RYN 54.72
- LGND 92.89
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.